Next Article in Journal
Recent Advances in the Discovery and Development of Marine Microbial Natural Products
Next Article in Special Issue
Improved Detection of Domoic Acid Using Covalently Immobilised Antibody Fragments
Previous Article in Journal / Special Issue
Biochemical and Electrophysiological Characterization of Two Sea Anemone Type 1 Potassium Toxins from a Geographically Distant Population of Bunodosoma caissarum
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2013, 11(3), 680-699;

Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management

Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI 48824, USA
Author to whom correspondence should be addressed.
Received: 21 December 2012 / Revised: 14 February 2013 / Accepted: 15 February 2013 / Published: 7 March 2013
(This article belongs to the Special Issue Marine Neurotoxins)
Full-Text   |   PDF [904 KB, uploaded 24 February 2015]   |  


Neuropathic pain afflicts a large percentage of the global population. This form of chronic, intractable pain arises when the peripheral or central nervous systems are damaged, either directly by lesion or indirectly through disease. The comorbidity of neuropathic pain with other diseases, including diabetes, cancer, and AIDS, contributes to a complex pathogenesis and symptom profile. Because most patients present with neuropathic pain refractory to current first-line therapeutics, pharmaceuticals with greater efficacy in pain management are highly desired. In this review we discuss the growing application of ω-conotoxins, small peptides isolated from Conus species, in the management of neuropathic pain. These toxins are synthesized by predatory cone snails as a component of paralytic venoms. The potency and selectivity with which ω-conotoxins inhibit their molecular targets, voltage-gated Ca2+ channels, is advantageous in the treatment of neuropathic pain states, in which Ca2+ channel activity is characteristically aberrant. Although ω-conotoxins demonstrate analgesic efficacy in animal models of neuropathic pain and in human clinical trials, there remains a critical need to improve the convenience of peptide drug delivery methods, and reduce the number and severity of adverse effects associated with ω-conotoxin-based therapies. View Full-Text
Keywords: neuropathic pain; voltage-gated calcium channel; omega-conotoxin; ziconotide neuropathic pain; voltage-gated calcium channel; omega-conotoxin; ziconotide

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Hannon, H.E.; Atchison, W.D. Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management. Mar. Drugs 2013, 11, 680-699.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top